Treatment of severe Crohn's disease using antimycobacterial triple therapy — approaching a cure?
Authors:
- T.J. BorodyTBT.J. Borody
- S. LeisSLS. Leis
- E.F WarrenEWE.F Warren
- R. SuraceRSR. Surace
- 1 January 2002
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 34 (1) , 29-38
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Etiological Role of Mycobacterium in Crohn’s Disease: An Assessment of the LiteratureDigestive Diseases, 1999
- Activities of Clarithromycin, Azithromycin, and Ofioxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage Mycobacterium avium-Mycobacterium intracellulareThe Journal of Infectious Diseases, 1995
- Controlled trial of antimycobacterial therapy in Crohn's diseaseDigestive Diseases and Sciences, 1991
- Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agentsagainst strains of Mycobacterium paratuberculosisJournal of Antimicrobial Chemotherapy, 1991
- Activity of rifabutin alone and in combination with clofammine, kanamycin and ethambutol against Mycobacterium intracellulare infections in miceTubercle, 1989
- ANTIMYCOBACTERIAL THERAPY INEFFECTIVE IN CROHN'S DISEASE AFTER A YEARThe Lancet, 1989
- Comparative in vitro and in vivo activity of rifabutin and rifampicin against mycobacterium avium complexTubercle, 1988
- Controlled trial of rifampicin and ethambutol in Crohn's disease.Gut, 1984
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980
- Dapsone in crohn's diseaseThe Lancet, 1975